Semaglutide vs Tirzepatide: Which Should You Microdose?

If you've decided you want to microdose a GLP-1 drug, the next question is which one — semaglutide or tirzepatide? They are the two molecules behind nearly every microdosing conversation online, and people swap between them as if the choice is obvious. It isn't. This page is an honest head-to-head for someone weighing that decision: how the two drugs differ in mechanism, what the trials say about their full-dose performance, how they compare on side effects and cost, and — most importantly — what changes (and what doesn't) when you shrink either one to a fraction of its tested dose.

The headline upfront: at full doses, the trials give tirzepatide an efficacy edge; at a microdose, no trial has compared the two, so the decision comes down to the same trade-offs as full dosing, just scaled down into territory neither drug was designed for. Let's walk through it.

Two different molecules, two different mechanisms

The first real difference is biological, and it's the one most worth understanding before you pick.

Semaglutide is a single agonist — it mimics the gut hormone GLP-1 and acts on the GLP-1 receptor alone. That drives glucose-dependent insulin release, glucagon suppression, slowed stomach emptying, and reduced appetite through the brain.

Tirzepatide is a dual agonist — it activates the GLP-1 receptor and the GIP receptor. The GIP arm is the extra ingredient: in combination with GLP-1 activity, it appears to amplify the metabolic and weight effects beyond what GLP-1 alone delivers. That second receptor is the whole reason tirzepatide is often framed as the "stronger" option.

Both mechanisms are exposure-dependent — they need enough drug present to occupy enough receptors to change appetite and metabolism. That single fact is the hinge for everything that follows, because a microdose deliberately reduces exposure. We cover each drug on its own in microdosing semaglutide and microdosing tirzepatide.

The full-dose efficacy gap: what the trials show

Here is where the comparison has real, high-quality evidence — at full, titrated doses.

For semaglutide, STEP 1 produced roughly 14.9% mean weight loss at the 2.4 mg maintenance dose in adults with overweight or obesity, versus about 2.4% on placebo¹. That's a large, well-replicated result.

For tirzepatide, SURMOUNT-1 produced roughly 15–21% mean weight loss across its 5, 10, and 15 mg tiers in adults with obesity — climbing higher in the upper tiers². On its face, the top of tirzepatide's range clears the top of semaglutide's.

But the cleanest comparison isn't reading two separate trials side by side — it's the one study that put both drugs in the same room. SURPASS-2 was a direct head-to-head, randomizing people with type 2 diabetes to tirzepatide (5, 10, or 15 mg) or semaglutide (1 mg). Tirzepatide beat semaglutide on both HbA1c reduction and weight loss, with a clear gradient across its tiers³. That is the strongest single piece of evidence in the whole comparison: under matched conditions, tirzepatide outperformed semaglutide.

Two honest caveats keep that from settling the microdosing question. First, SURPASS-2 compared tirzepatide against semaglutide 1 mg — a diabetes dose, not the 2.4 mg used for weight management — so it isn't a perfect efficacy match for the obesity setting. Second, and far more important: every number here came from full therapeutic doses. None of it was generated at a microdose.

How the efficacy gap translates to a microdose: it doesn't, cleanly

Here's the part the "tirzepatide is just better, so microdose that" logic skips. The full-dose edge was measured at 5–15 mg of tirzepatide against 1–2.4 mg of semaglutide. A microdose of either drug sits below the lowest rung of its own approved ladder — for semaglutide, below the 0.25 mg starter step; for tirzepatide, below the 2.5 mg starter step.

At those sub-therapeutic levels, nobody has measured whether tirzepatide's dual-agonist advantage survives the shrink, holds steady, or evaporates. The GIP arm might still contribute at low exposure, or it might fall below a threshold where it does little — there's no trial to tell us. So "tirzepatide wins at full dose, therefore tirzepatide wins at a microdose" is an assumption dressed up as a conclusion. The honest position is that the full-dose efficacy gap does not automatically carry down to microdose territory, because that territory has never been studied for either drug. For why lower doses generally do less across this class, see GLP-1 dose-response: why lower doses do less, and for what people actually report, how much weight can you lose microdosing GLP-1.

Tolerability: similar problems, dose still matters

People often reach for microdosing specifically to dodge side effects, so the tolerability comparison matters. Both drugs share the same core gastrointestinal profile — nausea, vomiting, constipation, diarrhea — because both slow gastric emptying through GLP-1 activity. In SURPASS-2's head-to-head, the GI side-effect rates were broadly comparable between the two drugs³, so there isn't a clean "one is gentle, one is harsh" story at full dose.

What's true for both: a smaller dose may soften dose-related side effects, but it doesn't make either molecule risk-free, and the nausea-from-slowed-emptying mechanism doesn't simply switch off at low doses. Tolerability is a reason to titrate carefully — not a reason to assume one drug is inherently safe in microdose form. We compare this directly in microdose vs full-dose GLP-1 side effects.

Cost and availability: the practical tilt

For many people the deciding factor isn't the trial data at all — it's price and access, and here the two drugs differ in ways worth naming.

Brand semaglutide (Ozempic, Wegovy) and brand tirzepatide (Mounjaro, Zepbound) are both expensive at list price, and neither is sold in a microdose strength — there's no pharmacy product designed to dispense a fraction of a starter dose. That means microdosing either one almost always routes through compounded product, where the cost and availability picture shifts again and varies by provider, sourcing, and the shifting regulatory status of GLP-1 compounding. Tirzepatide's compounded supply and pricing have moved on a different timeline than semaglutide's, so "which is cheaper to microdose" is a moving target rather than a fixed answer — check current provider pricing rather than trusting a number you read months ago. We rank providers on price and oversight at our GLP-1 microdose rankings hub.

So which should you microdose?

Strip it down and the decision mirrors the full-dose choice, scaled into untested territory:

• •If you lean toward the molecule with the stronger full-dose evidence, that's tirzepatide — SURPASS-2 gave it a direct head-to-head win, and SURMOUNT-1's top tiers reached higher weight loss than STEP 1²³. Just don't assume that edge transfers cleanly to a microdose.
• •If your priority is the longer track record and more cardiovascular and outcomes data, semaglutide has the deeper, older evidence base¹.
• •If cost and current availability decide it, that's a per-provider, per-month question, not a property of the molecule.

What no honest version of this comparison can give you is a microdose trial pitting one against the other. None exists. The only clinical literature addressing GLP-1 microdosing directly is cautionary — it describes a practice that grew up amid compounding restrictions and warns about dosing errors, pen manipulation, medication sharing, and unregulated sourcing, for both drugs alike⁴. That caution applies equally whichever molecule you choose.

The honest bottom line

At full doses, the evidence favors tirzepatide — most clearly in SURPASS-2, the one trial that compared them head to head³. But "microdose the stronger drug" rests on an assumption no study has tested: that a dual-agonist advantage measured at 5–15 mg survives being cut to a fraction of a starter dose. Both drugs are off-label as microdoses, both are usually compounded, neither comes in a microdose strength, and neither has a microdosing trial behind it. So the choice between them isn't really a microdosing question at all — it's the same trade-off you'd weigh at full dose (efficacy edge vs. track record vs. cost), carried down into a dose range where the evidence simply runs out. Go in clear-eyed, and talk to a qualified clinician before you commit to either one.

For more, see our deep dives on microdosing semaglutide and microdosing tirzepatide, our look at the brand-name versions in microdosing Ozempic and microdosing Zepbound, and our practical microdose calculator to see how a sub-dose maps onto a pen or vial.